Key Takeaways Novartis' core EPS rose to $2.25 from $2.06, as sales increased 8% to $13.9 billion.Kisqali, Kesimpta, Pluvicto and Scemblix drove growth, offsetting generic hits to Entresto and Tasigna.Novartis agreed to buy Avidity for $12B to strengthen its neuroscience pipeline.Swiss pharma giant Novartis AG (NVS) reported core earnings per share (excluding one-time charges) of $2.25 in the third quarter, which missed the Zacks Consensus Estimate by a penny. Nonetheless, the figure was up from $2.06 repor ...

ANALYSIS: Are Prediction Markets Turning Brokers Into Bookies? Notably, sales of heart-failure treatment Entresto fell 1%, in constant currency, to $1.88 billion. Entresto is facing off with generic competition. Generics took a 7 percentage-point hit on Entresto sales, Novartis said in its news release. Novartis reaffirmed its outlook for the year. Sales are expected to grow by a high single-digit percentage, while core operating income is projected to increase by a low-teens percentage. Analysts projected ...

Novartis (NYSE:NVS) Q3 2025 Earnings Call October 28, 2025 09:00 AM ET Company ParticipantsRichard Foster - Client Care SpecialistVasant Narasimhan - CEOSimon Baker - Head of Global Biopharma Research at Rothschild and CoThibault Boutherin - Executive Director of Equity ResearchHarry Kirsch - CFOJames Quigley - Executive Director of European Pharma and Biotech Equity ResearchSloan Simpson - Head of Investor RelationsConference Call ParticipantsNone - Analyst 2Rajesh Kumar - Team Head of Senior Global Health ...

Novartis AG Financial Performance and Market Position AnalysisNovartis AG (NYSE:NVS), a leading global healthcare company, is renowned for its innovative pharmaceuticals. The company is a key player in the pharmaceutical industry, competing with giants like Pfizer and Merck. On October 28, 2025, Novartis reported an earnings per share (EPS) of $2.25, slightly below the expected $2.26. However, the company achieved a revenue of approximately $13.9 billion, surpassing the estimated $13.8 billion, as reported ...

Novartis (NYSE:NVS) Q3 2025 Earnings Call October 28, 2025 09:00 AM ET Speaker3Good morning and good afternoon, and welcome to the Novartis Q3 2025 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be in a listen-only mode, and the conference is being recorded. After the presentation, there'll be an opportunity to ask questions by pressing star one and one at any time during the conference. Please limit yourself to one question and return to th ...

Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subsidiary of Novartis. “The acquisition of Tourmaline Bio aligns with our strategy to deepen expertise in areas where Novartis can lead and add valu ...

Content Click below to navigate through the document Company overview Financial review Conclusions Investor presentation October 28, 2025 Novartis Q3 Results | October 28, 2025 1 Content Click below to navigate through the document Appendix References Q3 2025 Results Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be i ...

You've really been spoiling the markets over the last 10 quarters. You've always beat expectations and then subsequently you were able to raise your guidance. You beat this time around even though it was a very narrow beat, but you didn't quite manage to raise your guidance.Talk to us about what you saw this quarter and why you're a little more cautious than in previous quarters maybe. >> Well, I think this is the first time in many quarters where we've had some generic expiries hit us. you know when you ac ...

（原标题：美股前瞻 | 三大股指期货齐涨，日对美投资大单或成美股牛市催化剂） 1. 10月28日(周二)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.27%，标普500指数期货涨0.03%，纳指期货涨0.12%。 2. 截至发稿，德国DAX指数涨0.16%，英国富时100指数跌0.07%，法国CAC40指数涨0.14%，欧洲斯托克50指数涨0.16%。 3. 截至发稿，WTI原油跌1.24%，报60.55美元/桶。布伦特原油跌1.17%，报64.14美元/桶。 市场消息 特朗普东京晚宴邀OpenAI、赛富时(CRM.US)CEO齐聚，共庆日对美投资大单。美国总统特朗普在结束对东京的访问前夕，计划与多位企业领袖 共进晚餐，届时将宣布日本对美投资成果。受邀嘉宾包括赛富时掌门马克·贝尼奥夫、东芝首席执行官岛田太郎、乐天集团创始人三木谷浩史等。 此次晚宴将在美国驻日大使乔治·格拉斯官邸举行，与会者还包括OpenAI联合创始人格雷格·布罗克曼、本田汽车(HMC.US)社长三部敏宏，以及安 杜里尔工业公司创始人帕尔默·勒基。此次晚宴适逢白宫宣布新一轮对美经济投资承诺。根据此前贸易框架，特朗普降低并设定了日本商品 ...

Shares in Swiss drugmaker Novartis were seen down 3.3% in pre-market trade on Tuesday after the company reported third-quarter profitability below market expectations, even as higher sales from key me... ...